National News

February edition of CPN magazine is out

PSNC News - 21 February 2020 - 1:55pm

The February 2020 edition of PSNC’s Community Pharmacy News (CPN) is now available. This month’s CPN features:

  • National audit determined;
  • PSNC CEO Blog;
  • PQS declaration period underway; and
  • How to endorse instalment forms.

View our CPN magazine online via the flipbook reader below or download the PDF copy. Please note, the colour PDF can be printed out in black-and-white and will still be clear to read.

Categories: National News

Updated Price Concessions – February 2020

NPA News - 21 February 2020 - 11:30am
Drug Price Concession Amiodarone  tablets 200mg (NEW) (28) £2.55 Co-careldopa tablets 25mg/100mg (100) £11.98 Desmopressin  tablets 200microgram(NEW) (30) (NEW) £19.47 Fluoxetine capsules 10mg (30) £46.89 Frovatriptan tablets 2.5mg (6) £10.18 Hydroxyzine tablets 10mg (84) £2.10 Hydroxyzine tablets 25mg (28) £0.90 Irbesartan tablets 150mg (28) £5.00 Irbesartan 300mg / Hydrochlorothiazide 12.5mg tablets (28) £4.74 Lymecycline  capsules 408mg (NEW) (28) £6.50 Meloxicam tablets 7.5mg (NEW) (30) £3.25 Meloxicam tablets 15mg (30) £5.71 Memantine tablets 10mg (28) £2.65 Memantine tablets 20mg (28) £7.40 Mirtazapine  tablets 15mg (NEW) (28) £2.20 Mirtazapine tablets 30mg (NEW) (28) £2.20 Mirtazapine tablets 45mg (NEW) (28) £2.52 Nitrazepam tablets 5mg (28) £3.10 Pizotifen  tablets 1.5mg (NEW) (28) £5.75 Quinine sulfate tablets 300mg (28) £6.99 Ranitidine  tablets 150mg (NEW) (60) £6.80 Ranitidine  tablets 300mg (NEW) (30) £6.14 Rivastigmine capsules 3mg (28) £3.95 Tolterodine  tablets 2mg (NEW) (56) £4.58 Trihexyphenidyl  tablets 2mg  (NEW) (84) £7.50 Venlafaxine  tablets 37.5mg (NEW) (56) £6.94 Venlafaxine tablets 75mg (NEW) (56) £14.20…
Categories: National News

February 2020 Price Concessions – 2nd update

PSNC News - 21 February 2020 - 11:00am

Department of Health and Social Care (DHSC) has today granted the following list of price concessions:

Drug Pack size Price Concession Amiodarone 200mg tablets 28 £2.55 Desmopressin 200microgram tablets 30 £19.47 Lymecycline 408mg capsules 28  £6.50 Meloxicam 7.5mg tablets 30  £3.25 Mirtazapine 15mg tablets 28  £2.20 Mirtazapine 30mg tablets 28  £2.20 Mirtazapine 45mg tablets 28  £2.52 Pizotifen 1.5mg tablets 28  £5.75 Ranitidine 150mg tablets 60  £6.80 Ranitidine 300mg tablets 30  £6.14 Tolterodine 2mg tablets 56  £4.58 Trihexyphenidyl 2mg tablets 84  £7.50 Venlafaxine 37.5mg tablets 56  £6.94 Venlafaxine 75mg tablets 56 £14.20

DHSC previously announced (19.02.20) the following list of price concessions:

Drug Pack size Price Concession Co-careldopa 25mg/100mg tablets 100 £11.98 Fluoxetine 10mg capsules 30 £46.89 Frovatriptan 2.5mg tablets 6 £10.18 Hydroxyzine 10mg tablets 84 £2.10 Hydroxyzine 25mg tablets 28 £0.90 Irbesartan 150mg tablets 28 £5.00 Irbesartan 300mg / Hydrochlorothiazide 12.5mg tablets 28 £4.74 Meloxicam 15mg tablets 30 £5.71 Memantine 10mg tablets 28 £2.65 Memantine 20mg tablets 28 £7.40 Nitrazepam 5mg tablets 28 £3.10 Quinine sulfate 300mg tablets 28 £6.99 Rivastigmine 3mg capsules 28 £3.95

PSNC is still working with the DHSC to agree further concessionary prices on other drugs reported to be unavailable at the stated February 2020 Drug Tariff price. Contractors will be alerted to further updates to the price concession list through our website and via our e-news email.  If you wish to subscribe to our email list, you can receive an email as soon as any announcements are made. Please note that PSNC cannot provide details of any generic products awaiting price concession approval from DHSC.No additional endorsements are required for price concessions. A price concession only applies for the month in which it is granted.

If you have problems obtaining a Part VIII product or problems obtaining the product at the stated Drug Tariff price, please report the issue to PSNC using the online feedback form on the PSNC Website.
Please include full details of the supplier and price paid for any products sourced above the Drug Tariff price. PSNC will investigate the extent of the problem and if appropriate discuss the issue with DHSC.

Categories: National News

Supply Notification: H2-antagonists (Cimetidine, Famotidine and Nizatidine) – update

PSNC News - 20 February 2020 - 3:35pm

Update (20/02/2020): resupply dates now expected:

  • Famotidine 20mg tablets are out of stock until the end of February 2020 (Tilomed) Mid March 2020 (Teva) 
  • Cimetidine 200mg tablets are out of stock until the end of March 2020 (Ennogen) May 2020 (Medley Pharma)
  • Nizatidine 150mg and 300mg tablets: No confirmed resupply date (Medreich and Mylan)

Department of Health and Social Care (DHSC) has issued a medicine supply notification for H2-antagonists (Cimetidine, Famotidine and Nizatidine)

Suppliers of Cimetidine, Famotidine and Nizatidine have reported an increase in demand, which has contributed to short term shortages of Cimetidine 200mg tablets, Famotidine 20mg tablets, and Nizatidine 150mg and 300mg tablets.

  • Famotidine 20mg tablets are out of stock until the end of December 2019.
  • Cimetidine 200mg tablets are out of stock until the end of January 2020.
  • Nizatidine 150mg and 300mg tablets are out of stock until February 2020.

The DHSC Medicine Supply Team provide a monthly update on potential supply issues affecting both primary and secondary care. This update is uploaded on the Specialist Pharmacy Services (SPS) website. To register, you will need  an NHS email address. Once set up and logged in, you will be able to access it online.

Categories: National News

Shortage Notice: Salofalk (mesalazine) suppositories (500mg and 1g) – Update

PSNC News - 20 February 2020 - 3:32pm

Update (20/02/2020): resupply date now expected mid April 2020 for the 500mg suppositories, mid September 2020 for the 1g suppositories

First published 24th October 2019

Dr Falk the sole supplier of the 500mg mesalazine suppository (Salofalk suppositories 500mg) has announced that they expect to be out of stock of this line until mid-December 2019. The company also expect to be out of stock of the 1g suppository (Salofalk suppositories 1g) from late November to mid-December.

Alternative agents and management options
The guidance issued states ‘NICE support the first-line use of topical aminosalicylates (including mesalazine suppositories) to induce remission in people with a mild-to-moderate first presentation or inflammatory exacerbation of ulcerative proctitis. They also recommend that a topical aminosalicylate (daily or intermittent) should be considered to maintain remission after a mild-to-moderate exacerbation of ulcerative proctitis.

In the absence of Salofalk suppositories the most practical short-term management option is to convert patients to Pentasa suppositories. For patients being treated with the 1g strength this is a straight forward conversion – the dose regimen is identical for both brands.
However, for patients being treated with the 500mg strength it is less straight forward – patients could be receiving doses ranging from 500mg twice daily through to 1 g three times a day.’ 

Suggested dose changes are as follows*

Existing regimen Proposed regimen Proposed regimen 500mg twice daily 1 g daily 500mg three times daily Either 1 g daily (within licence) or 1g twice daily (off label) 2x500mg suppositories twice daily 1g twice daily (off label) 2x500mg suppositories three times daily 1g three times daily (off label) 1g three times daily (off label)

*as per the UKMi memo 

View the full memo on the Specialist Pharmacy Service website here.

For more information on medicines shortages, click here.

To report a medicine shortage, click here.

Categories: National News

Shortage Notice: Seroxat (paroxetine) 20mg/10ml oral solution – Update

PSNC News - 20 February 2020 - 3:31pm

Update (20/02/2020): resupply date now expected early March 2020

First published 25th October 2019

The Department of Health and Social Care (DHSC) have advised that paroxetine 20mg/10ml oral solution will be out of stock until January 2020 due to manufacturing delays. Paroxetine tablets remain available from various suppliers.

Action required: 

For patients who do not have sufficient supplies of paroxetine 20mg/10ml oral solution for the duration of the expected out of stock period, clinicians should consider the alternatives below as soon as possible.

  • Prescribing paroxetine tablets in place of oral solution.
  • UK Medicines Information (UKMi) have advised that tablets can be crushed and mixed with water for administration, however this would be an off-label use. The crushed tablets are bitter and have a slight local anaesthetic effect.
  • Prescribing an unlicensed preparation of paroxetine 20mg/10ml oral solution, which is currently available to order from the following importers – Clinigen, WEP Clinical, Mawdsleys and Target Healthcare Ltd.
  • Clinicians will need to work with local pharmacies to understand which specific unlicensed products can be sourced and lead times. The price of specials varies.

Pharmacy team are reminded that where a prescriber wishes you to dispense an import, prescriptions must be annotated ‘specials/unlicensed import’.

A prescription calling for the unlicensed product should be endorsed as follows:

  • Quantity dispensed
  • Pack size
  • Price per unit less any discount/rebate
  • Manufacturer/importer MHRA license number
  • Batch number
  • Specials procurement fee endorsement of ‘SP’

As a reminder, all prescriptions for unlicensed medicines should be placed in the red separators for the end of month submission.

See our factsheet for further guidance on endorsing unlicensed specials and imports.

For more information on medicines shortages, click here.

To report a medicine shortage, click here.

If you have any queries, please contact DHSCmedicinesupplyteam@dhsc.gov.uk

Categories: National News

Sayana Press (medroxyprogesterone acetate) injection supply issue – Update

PSNC News - 20 February 2020 - 3:29pm

Update (20/02/2020): resupply date now expected March 2020

First published 23rd August 2019

Pfizer, the sole supplier of Sayana Press (medroxyprogesterone acetate 104mg) in the UK,  have informed the Department of Health and Social Care that due to  manufacturing delays, Sayana Press will be out of stock until at least the end of 2019.

Depo-Provera (medroxyprogesterone acetate 150mg) is currently available and able to support the market during this time, should clinicians deem a switch appropriate.

If you have any queries please contact DHSCmedicinesupplyteam@dhsc.gov.uk

 

Categories: National News

Supply Notification: Lorazepam (Ativan®) 4mg/ml injection (Pfizer)

PSNC News - 20 February 2020 - 3:28pm

Department of Health and Social Care (DHSC) has issued a medicine supply notification for Lorazepam (Ativan®) 4mg/ml injection (Pfizer).

Pfizer have limited supplies of Lorazepam (Ativan®) 4mg/ml injection and anticipate going out of stock by 6th March 2020. The anticipated re-supply date is w/c 16th March 2020

The DHSC Medicine Supply Team provide a monthly update on potential supply issues affecting both primary and secondary care. This update is uploaded on the Specialist Pharmacy Services (SPS) website. To register, you will need  an NHS email address. Once set up and logged in, you will be able to access it online.

Categories: National News

Shortage Notice: Salbutamol 2mg/5ml syrup update

PSNC News - 20 February 2020 - 3:28pm

Update (20/02/2020): resupply date now expected end of March 2020

GlaxoSmithKline (GSK) and Pinewood, the manufacturers of Salbutamol 2mg/5ml syrup, are currently experiencing temporary disruptions.

GSK, the main supplier of Salbutamol 2mg/5ml syrup (Ventolin) have advised a resupply date of early August 2019

Pinewood are long term out of stock due to manufacturing issues and  are currently unable to advise a resupply date.  

Supplies are available from specialist importers on an ‘unlicensed’ basis. Ensure that where a prescriber wishes you to dispense an import, prescriptions are annotated ‘specials/unlicensed’ and are endorsed as follows:

  • Amount dispensed over pack size used;
  • Invoice price per pack size from which the order was supplied less any discount or rebate;
  • Manufacturers’/importers’ MHRA licence number;
  • Batch number of the product supplied;
  • SP

More information and details of alternative products can be found here on the SPS website.

Categories: National News

Supply Notification: Penicillamine 125mg and 250mg tablets

PSNC News - 20 February 2020 - 3:22pm

Department of Health and Social Care (DHSC) has issued a medicine supply notification for Penicillamine 125mg and 250mg tablets.

  • Penicillamine 125mg tablets are out of stock until late March 2020.
  • Penicillamine 250mg tablets are out of stock, with an anticipated re-supply date end of February 2020.

Further information can be found on the Specialist Pharmacy Services (SPS) website here.

The DHSC Medicine Supply Team provide a monthly update on potential supply issues affecting both primary and secondary care. This update is uploaded on the Specialist Pharmacy Services (SPS) website. To register, you will need  an NHS email address. Once set up and logged in, you will be able to access it online.

Categories: National News

Class 4 drug alert – Ibuprofen tablets 400mg Crescent Pharma Ltd and Flamingo Pharma (UK) Ltd

NPA News - 20 February 2020 - 3:11pm
Ref: EL (20)A/10 20 February 2020 A Class 4 drug alert has been issued by the Medicines & Healthcare products Regulatory Agency (MHRA).  Crescent Pharma Ltd and Flamingo Pharma (UK) Ltd have informed the MHRA that the Patient Information Leaflet (PIL) for specific batches of Ibuprofen tablets 400mg is incorrect Further information can be found on the MHRA section on the GOV.UK website. Produced by the NPA Pharmacy Services team February 2020…
Categories: National News

Displaying COVID-19 posters – advice for pharmacy teams

NPA News - 20 February 2020 - 2:22pm
Public Health England (PHE) are advising pharmacies to prominently display the following two posters so that they can clearly be seen by patients wishing to enter the pharmacy premises: Poster for outside pharmacies, GPs and other NHS settings Affected countries and places poster Additional PHE posters including COVID-19 public information and home isolation advice are available on the NPA website The NPA has published a dedicated webpage to COVID-19 with country specific posters. The following resources have also been produced to support pharmacy teams in the provision of advice for patients wanting more information on COVID-19: COVID-19 – pharmacy team guide: this details the signs and symptoms of COVID-19 and provides advice for pharmacy teams COVID-19 – poster for pharmacy teams: a quick go-to guide for pharmacy teams to prevent the risk of infection For further information please contact the NPA Pharmacy Services team on 01727 891800 or email at: pharmacyservices@npa.co.uk. Produced by the NPA Pharmacy Services team February 2020.…
Categories: National News

Class 4 Drug Alert: Ibuprofen 400mg Tablets (Crescent Pharma Ltd and Flamingo Pharma (UK) Ltd)

PSNC News - 20 February 2020 - 12:12pm

Drug alert number: EL (20)A/10

Date issued: 20 February 2020

The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 pharmacy level caution in use for:

Crescent Pharma Ltd, Flamingo Pharma (Uk) Ltd, Ibuprofen 400mg Tablets (Various Liveries)

Crescent Pharma Ltd and Flamingo Pharma (UK) Ltd have informed the MHRA that the Patient Information Leaflet (PIL) within their packs of pharmacy (P) batches listed below are incorrect. The PIL in the below listed batches includes incorrect dosing instructions in Section 3, How to take Ibuprofen. The leaflet incorrectly states that ‘The maximum daily dose should not exceed 6 [six] tablets (2400 mg).’ This dosing regimen should only be given to patients who are under the supervision of their GP or healthcare prescriber and have been prescribed Ibuprofen 400mg Tablets. The outer carton contains the correct P indications and posology.

Crescent Pharma Ltd Ibuprofen 400mg Tablets (Almus Livery) PL 20416/0089 Batch Number Expiry Date Pack Size First Distributed DO3210N, DO3410N, DO3510N 09.2022 84 11 Jun 19 DO3310N  09.2022 84 07 Aug 19 DO3610N 10.2022 84 18 Jul 19 DO3710N, DO3811N 10.2022 84 12 Mar 19 DO3911N 10.2022 84 19 Jul 19 Ibuprofen 400mg Tablets (Crescent Livery) PL 20416/0089 Batch Number Expiry Date Pack Size First Distributed 001205M 04.2021 84 08 Aug 19 DO0101O 12.2022 84 10 Jan 20 DO0503O 02.2023 84 10 Jan 20 Flamingo Pharma (UK) Ltd Ibuprofen 400mg Tablets (Flamingo Pharma Livery) PL 43461/0005 Batch Number Expiry Date Pack Size First Distributed 1402177 Aug-23 24 Oct-18 1402268 Sep-23 48 Nov-18 1402278 Oct-23 24 Dec-18 1402308, 1402309, 1402310 Nov-23 84 Dec-18 1402316, 1402317 Nov-23 84 Jan-19 1402318 Dec-23 24 Jan-19 1402337, 1402338 Dec-23 48 Jan-19 1402363, 1402353, 1402354 Dec-23 48 Mar-19 1402352, 1402361, 1402362 Dec-23 84 Mar-19 1402368 Jan-24 48 Mar-19 1402369,1402370 Jan-24 24 Mar-19 1402424 Mar-24 24 Apr-19 1402425 Mar-23 48 Apr-19 1402543, 1402544 Mar-24 48 Jul-19 1402554 Jun-24 24 Jul-19 1402557 Jun-24 84 Aug-19 1402558, 1402559 Jun-24 48 Aug-19 1402622, 1402623 Jul-24 48 Sep-19 1402624, 1402625, 1402628 Jul-24 24 Sep-19 1402670, 1402671, 1402672, 1402673 Aug-24 24 Nov-19 1402674, 1402686, 1402687, 1402688, 1402705 Sep-24 48 Nov-19 1402706 Sep-24 84 Nov-19 1402707, 1402708 Oct-24 48 Dec-19 1402709, 1402710 Oct-24 84 Dec-19 1402711 Nov-24 84 Jan-20 1402837, 1402838 Dec-24 24 Feb-20 1402854 Dec-24 48 Feb-20 1402839, 1402852 Dec-24 96 Feb-20 1402853 Dec-24 84 Feb-20 Ibuprofen 400mg Tablets (TEVA Livery) PL 43461/0005 Batch Number Expiry Date Pack Size First Distributed 1402172, 1402173 Jul-23 84 Sep-18 1402174, 1402175, 1402176, 1402178 Aug-23 84 Oct-18 1402279 Nov-23 84 Dec-18 Advice for healthcare professionals

When dispensing or providing this product over the counter, please check the Marketing Authorisation Holder and the batch number; if any of the above batch numbers are being dispensed, ensure that patients are aware of the correct dosage instructions and maximum daily dose as stated on the carton labelling.

• Correct statement: The maximum daily dose should not be more than 3 [three] tablets (1200 mg).

Where possible, these packs should be considered to be dispensed against a prescription rather than sold over the counter to safeguard patients from taking a prescription only dose.

Full details of the drug alert can be viewed herehere.

Further Information

Crescent Pharma Ltd.
• For updated PIL information, please click here.
• For more information or medical information queries, please contact: Crescent Pharma Ltd. Medical Information Department on +00351 214643225, via email on tiago.barca@pharsolution.com or +44 (0) 1256 772740.

Flamingo Pharma (UK) Ltd.
• For more information or medical information queries, please contact: Flamingo Pharma (UK) Ltd on +44 (0) 7733 522465

 

Categories: National News

Ask PSNC: Pharmacy Quality Scheme FAQs

PSNC News - 20 February 2020 - 12:08pm

The team at PSNC has received a number of queries on the Pharmacy Quality Scheme (PQS). Below are some of the questions asked in recent weeks.

 

Q. How do I enter the details of my Primary Care Network Pharmacy Lead in the MYS PQS declaration?
A. During completion of the PQS declaration, contractors will be asked to enter the name of the Pharmacy PCN lead. The contractor will be presented with a blank text field in which either the PCN name, the Lead’s name, the Lead’s pharmacy or the Lead’s pharmacy’s F code may be entered.

Once some text has been entered, the system will present the contractor with a list of related results. Clicking on an item from this list will automatically enter the full details in the text field. If the wrong item is selected, this can be deleted by the contractor and a further search carried out.

In an instance where the NHSBSA has no data relating to the PCN, text can be entered manually without the use of the related results.

There have been a small number of changes to the Pharmacy Lead in some PCNs since the time that the data was collated by the NHSBSA. If you believe that the name of the PCN Lead given by the MYS system is incorrect, enter the details you believe to be correct. In these rare cases, it will help with post-payment verification to follow up your declaration with an email to the NHSBSA (nhsbsa.pharmacysupport@nhs.net) to make them aware of the situation.

The NHSBSA Provider Assurance Team will review and update the PCN Pharmacy Lead data file following the submission of declarations to help support the inclusion of pharmacies in the development of PCNs.

Q. I didn’t undertake the diabetes criterion within the Prevention domain, but there doesn’t seem to be a way to record that on MYS. What should I do to complete my declaration?
A. MYS has not been configured to allow a contractor to state they did not undertake the diabetes criterion, so where this is the case, the contractor will need to answer yes to the following question:

Did the pharmacy have any prescriptions for patients with diabetes aged 12 and over between 1 October 2019 and 31 January 2020?

The contractor should then complete the following six questions regarding the number of patient interactions by entering zero. The contractor will then be able to continue to make and submit their declaration. Once they have submitted their declaration, they should email the NHSBSA (nhsbsa.pharmacysupport@nhs.net) to highlight that they did not undertake the diabetes criterion and have had to use the workaround in the MYS declaration.

Q. What should I do if I have already completed my PQS declaration, but the PCN Pharmacy Lead has now changed to a different individual?
A. Your declaration of the name of the PCN Pharmacy Lead was correct at the time of declaration and made in good faith, so the change in the Lead will not affect the pharmacy’s PQS payment. To avoid the NHSBSA having to check with you about the name of the Pharmacy Lead when they undertake the validation of that data, you can email the NHSBSA (nhsbsa.pharmacysupport@nhs.net) to highlight the change in the Pharmacy Lead.

Where possible, it would also be appropriate for the previous Pharmacy Lead to email the NHSBSA to let them know that they are no longer the Lead.

Q. What should I do if I have made a mistake in my PQS declaration and have claimed for a criterion that I did not achieve?
A. Email the NHSBSA (nhsbsa.pharmacysupport@nhs.net) to let them know about the incorrectly claimed PQS criterion, so this can be amended in the MYS data before payments are calculated.

Q. What should I do if I have made a mistake in entering some of the data related to the audits I have undertaken as part of the PQS?
A. Incorrect audit data can be highlighted by emailing the NHSBSA (nhsbsa.pharmacysupport@nhs.net) to let them know and provide the correct audit data. It won’t be possible for your claim to be amended if you have not correctly claimed for a criterion, but it may be possible for the audit data to be amended in due course, to ensure the overall audit data reflects the activity that pharmacies undertook.

Q. When entering data on the medicines safety audits, I receive a message stating that “The total number who agreed or did not agree should not be more than the total number of patients dispensed [the medication]”. How do I proceed through the medicines safety audits when a number of patients did not agree to discuss their medication?
A. When entering figures in response to the questions below, these should total the number of patients who were dispensed the medication, regardless of whether the patients declined to discuss this with pharmacy staff:

How many patients (or their representatives) agreed to discuss their [medication, e.g. valproate] with a pharmacist at the pharmacy?
Agreed – 2
Did not agree – 2

How many patients were given advice and information in line with the MHRA Drug Safety Update 2018, including the potential impact on an unborn child?
Number given advice – 1
Number not given advice – 3

Further FAQS can be found on the Pharmacy Quality Scheme FAQs page.

Categories: National News

FreeStyle Libre Delays Now Resolved

PSNC News - 20 February 2020 - 11:50am

Abbott have advised that the temporary supply problems with FreeStyle Libre sensors have been resolved. Abbott has issued the following statement on 19th February 2020.

Abbott is sorry for the temporary delays in fulfilling FreeStyle Libre sensor orders and the impact this has had on the users as well as the wider diabetes community. The interruption in fulfilling orders was longer than anticipated and since then we have been working hard to rectify the situation. The delays have now been resolved.

FreeStyle Libre sensors are listed as an Appliance in Part IXA of the Drug Tariff which can be dispensed against NHS prescriptions. The sensors can only be ordered directly from Abbott through their pharmacy ordering portal.

PSNC has a resource relating to dispensing appliances and includes FAQs you may find helpful.

 

Categories: National News

Clinical governance deadlines fast approaching

PSNC News - 20 February 2020 - 10:42am

The end of the financial year (31st March) is approaching and community pharmacy contractors are reminded of four key deadlines relating to the clinical governance aspects of their terms of  service.

The clinical governance requirements of the Community Pharmacy Contractual Framework (CPCF) cover a range of quality related issues and are set out in Schedule 4 of the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013. Adherence with the clinical governance requirements is thus a part of the terms of service.

PSNC urges contractors to ensure that they have completed, or are working towards completing, the clinical governance requirements highlighted below to meet the end of year deadline.

Summary of actions to be completed by 31st March 2020

Topic Requirements By when? Data Security and Protection Toolkit

To use the Data Security and Protection Toolkit to complete and submit an annual information governance (IG) return.

See our Toolkit webpage for more information and guidance. 31st March 2020 Community Pharmacy Patient Questionnaire (CPPQ)

To conduct an annual CPPQ and publish the results.

See our CPPQ webpage for more information and guidance. 31st March 2020 Clinical audit

To conduct two audits each year: one on a topic of your choice* and one determined nationally by NHS England and NHS Improvement (the focus of the national audit for 2019/20 focusses on antimicrobial stewardship, specifically aimed at advice provided to patients on upper respiratory tract infections).

*Please note, any audits undertaken as part of the Pharmacy Quality Scheme cannot be used as the pharmacy’s own audit.

See our clinical audit webpage for more information and guidance. Pharmacy’s own audit deadline:
31st March 2020National audit deadline:
31st March 2020

A fourth clinical governance requirement, whilst not due by 31st March, should be completed shortly afterwards and as such it is best to begin work towards achieving this alongside the requirements listed above.

Complaints report To prepare an annual report each year and send a copy to the local NHS England team. As soon as practicable after
31st March 2020 PSNC guidance

To help support contractors in meeting the above requirements, PSNC’s Regulations and Support Team has also produced a quick reference guide identifying the actions to be completed by 31st March 2020, as well as details of ongoing clinical governance requirements.

PSNC Briefing 009/20: Upcoming clinical governance deadlines – actions to be completed by 31st March 2020

Categories: National News

Upcoming clinical governance deadlines – actions to be completed by 31 March 2020

PSNC News - 20 February 2020 - 10:14am

PSNC’s Regulations and Support Team is often asked questions about key actions and submission deadlines for the clinical governance aspects of the terms of service. This briefing is a quick reference guide identifying the actions to be completed by 31 March 2020 (Section A). The briefing also includes details of ongoing clinical governance requirements (Section B).

PSNC Briefing 009/20: Upcoming clinical governance deadlines – actions to be completed by 31 March 2020

If you have any queries on this PSNC Briefing or you require more information, please contact Layla Rahman, Regulations Officer.

To browse other PSNC Briefings on Contract and IT, click here.

View Article…

Categories: National News

National clinical audit topic announced for 2019/20 – Antimicrobial stewardship

NPA News - 19 February 2020 - 2:21pm
All community pharmacy contractors must participate in the annual national clinical audit during March 2020 as part of the Community Pharmacy Contractual Framework (CPCF) requirements. The agreed national audit by the Pharmaceutical Services Negotiating Committee (PSNC) and the NHSE&I for 2019/20, will concentrate on antimicrobial stewardship by provision of clinically suitable advice to patients seeking information on the management of upper respiratory tract infection (URTI) symptoms. The audit must be conducted in March 2020 (finishing no later than 31 March) over a consecutive period of five days, collecting data from a minimum of 10 patients. For full guidance and actions for pharmacy contractors on completing the audit, refer to the “2019/20 Community Pharmacy Contractual Framework national clinical audit: Antimicrobial stewardship” For further information on this or any other query, please contact the NPA Pharmacy Services team on 01727 891 800 or email pharmacyservices@npa.co.uk. Produced by the NPA Pharmacy Services team February 2020.…
Categories: National News

February 2020 Price Concessions – 1st update

PSNC News - 19 February 2020 - 10:00am

Department of Health and Social Care (DHSC) has today granted the following initial list of price concessions:

Drug Pack size Price Concession Co-careldopa 25mg/100mg tablets 100 £11.98 Fluoxetine 10mg capsules 30 £46.89 Frovatriptan 2.5mg tablets 6 £10.18 Hydroxyzine 10mg tablets 84 £2.10 Hydroxyzine 25mg tablets 28 £0.90 Irbesartan 150mg tablets 28 £5.00 Irbesartan 300mg / Hydrochlorothiazide 12.5mg tablets 28 £4.74 Meloxicam 15mg tablets 30 £5.71 Memantine 10mg tablets 28 £2.65 Memantine 20mg tablets 28 £7.40 Nitrazepam 5mg tablets 28 £3.10 Quinine sulfate 300mg tablets 28 £6.99 Rivastigmine 3mg capsules 28 £3.95

PSNC is still working with the DHSC to agree further concessionary prices on other drugs reported to be unavailable at the stated February 2020 Drug Tariff price. Contractors will be alerted to further updates to the price concession list through our website and via our e-news email.  If you wish to subscribe to our email list, you can receive an email as soon as any announcements are made. Please note that PSNC cannot provide details of any generic products awaiting price concession approval from DHSC.No additional endorsements are required for price concessions. A price concession only applies for the month in which it is granted.

If you have problems obtaining a Part VIII product or problems obtaining the product at the stated Drug Tariff price, please report the issue to PSNC using the online feedback form on the PSNC Website.
Please include full details of the supplier and price paid for any products sourced above the Drug Tariff price. PSNC will investigate the extent of the problem and if appropriate discuss the issue with DHSC.

Categories: National News
Syndicate content
Continuing Professional Development Just visiting this site means you are probably performing CPD - record it online at www.uptodate.org.uk
Site developed by Gary Warner
Drupal theme by Kiwi Themes.